Sign On to Support the Multi-Disease Therapeutic Designation

Members of Congress and Federal Health Policymakers

Sign On to Support the Multi-Disease Therapeutic Designation

Full proposal here


The Food and Drug Administration (FDA) has built an expedited drug development framework that has transformed how innovative therapies reach patients. Programs such as Breakthrough Therapy Designation, Fast Track, Accelerated Approval, Priority Review, and the Regenerative Medicine Advanced Therapy (RMAT) designation have shortened development timelines and accelerated the delivery of treatments for cancer, rare diseases, and other serious conditions.

However, these pathways were designed around a traditional model: one drug, one disease.

That framework is increasingly mismatched with a new class of investigational therapies designed to target the biological mechanisms that contribute to multiple chronic diseases of aging. Today, sponsors developing these therapies must navigate separate FDA review divisions for each disease indication, often facing inconsistent endpoint requirements and duplicative clinical trial expectations. The result is unnecessary delay, increased development costs, and reduced investment in therapies that could address several age-related diseases simultaneously.

A4LI's white paper proposes the creation of a Multi-Disease Therapeutic Designation (MDTD): a new expedited designation under 21 U.S.C. §356 modeled after successful pathways such as RMAT and the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD).

Under this proposal, an investigational therapy would qualify for MDTD if it is intended to address biological mechanisms common to two or more serious age-related chronic diseases and preliminary clinical evidence suggests the potential to address unmet medical needs.

The Proposal:

  • Requires no new appropriations and creates no new FDA office or program.

  • Does not lower FDA's safety or efficacy standards.

  • Establishes a dedicated expedited pathway for therapies that target multiple age-related diseases through shared biological mechanisms.

  • Builds on clear congressional precedent, including the creation of Breakthrough Therapy Designation through FDASIA (2012) and RMAT and LPAD through the 21st Century Cures Act (2016).

The upcoming PDUFA VIII reauthorization, covering FDA fiscal years 2028–2032, presents a natural legislative vehicle for this reform.

Chronic diseases account for approximately 90 percent of the nation's $4.9 trillion in annual healthcare expenditures, and nearly half of Medicare beneficiaries live with four or more chronic conditions. Creating a regulatory pathway specifically designed for therapies that address the shared biology underlying these diseases represents one of the most impactful and cost-effective reforms available to Congress during the upcoming reauthorization cycle.

Sponsored by

To: Members of Congress and Federal Health Policymakers
From: [Your Name]

To my Elected Officials,

I am writing as a constituent and supporter of the Alliance for Longevity Initiatives (A4LI) to urge your support for policies that modernize the development, testing, and evaluation of medical devices.

As the Committee begins work on reauthorizing the Prescription Drug User Fee Act (PDUFA VIII), we write to urge you to include a Multi-Disease Therapeutic Designation (MDTD) in the reauthorization package.

Decades of research in geroscience have shown that many chronic, age-related diseases share the same underlying biology. That has opened the door to a new class of therapies that could prevent or treat several conditions at once by targeting those common pathways, and a fast-growing biotechnology sector is now working on them. FDA's review process hasn't kept up. It still evaluates each disease on its own, so a sponsor developing one therapy that could help prevent several conditions has to run separate, duplicative development programs, one disease at a time.

An MDTD would give these prevention-focused therapies a dedicated, coordinated pathway at FDA. It is modeled on tools Congress has already created, including Breakthrough Therapy Designation, the Regenerative Medicine Advanced Therapy (RMAT) designation, and the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD). It requires no new appropriations and does not lower FDA's standards for safety or efficacy.

The need is large. Chronic disease accounts for about 90 percent of the nation's $4.9 trillion in annual health care spending, and more than one-third of Medicare beneficiaries live with four or more chronic conditions. Our constituents, and the programs that care for them, can't afford a system that treats these diseases one at a time after they appear. Supporting therapies that prevent several diseases before they progress is one of the most effective steps Congress can take to improve health outcomes and reduce long-term costs.

We respectfully urge the Committee to include the Multi-Disease Therapeutic Designation in the PDUFA VIII reauthorization. Thank you for your attention to this request and for your continued leadership on the health of the American people.